• DOI:10.1177/0269881116680924
Corpus ID: 52848530

Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology

@article{OBrien2017ClinicalPW,
  title={Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology},
  author={J. O'Brien and C. Holmes and M. Jones and R. Jones and G. Livingston and I. McKeith and P. Mittler and P. Passmore and C. Ritchie and L. Robinson and E. Sampson and J. Taylor and A. Thomas and A. Burns},
  journal={Journal of Psychopharmacology},
  year={2017},
  volume={31},
  pages={147 - 168}
}

J. O'Brien, C. Holmes, +11 authors A. Burns

Published 2017

Psychology, Medicine

Journal of Psychopharmacology

The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A–D, with A having the strongest evidence base (from randomised controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have… CONTINUE READING

View on SAGE

eprints.soton.ac.uk

Save to Library

Create Alert

Cite

Launch Research Feed